Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) EBITDA Margin (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed EBITDA Margin for 6 consecutive years, with 67983.33% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 163641667.0% to 67983.33% in Q3 2025 year-over-year; TTM through Sep 2025 was 191982.5%, a 79845868.0% increase, with the full-year FY2024 number at 507678.38%, down 50713373.0% from a year prior.
  • EBITDA Margin was 67983.33% for Q3 2025 at 4D Molecular Therapeutics, up from 396373.33% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 192900.0% in Q4 2023 to a low of 5611700.0% in Q4 2024.
  • A 5-year average of 475592.52% and a median of 13446.03% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -580460000bps in 2024, then soared 163641667bps in 2025.
  • 4D Molecular Therapeutics' EBITDA Margin stood at 26917.39% in 2021, then surged by 91bps to 2301.28% in 2022, then skyrocketed by 8482bps to 192900.0% in 2023, then plummeted by -3009bps to 5611700.0% in 2024, then surged by 99bps to 67983.33% in 2025.
  • Per Business Quant, the three most recent readings for FDMT's EBITDA Margin are 67983.33% (Q3 2025), 396373.33% (Q2 2025), and 383007.14% (Q1 2025).